Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597009 · ClinicalTrials.gov registry record · Phase 1
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
A Phase 1 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03597009 is a Phase 1 study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT03597009, a Phase 1 study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a Phase Ib/II clinical trial to evaluate the feasibility of administering talimogene laherparepvec into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.
Interventions
- DRUG Nivolumab
- DRUG Talimogene laherparepvec (TVEC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597009
The ClinicalTrials.gov registry entry for NCT03597009 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03597009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597009 about?
NCT03597009 is a clinical study titled "A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion". This is a Phase Ib/II clinical trial to evaluate the feasibility of administering talimogene laherparepvec into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.
What is the current status of trial NCT03597009?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2019-03-06. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT03597009?
The interventions under investigation include: Nivolumab (DRUG), Talimogene laherparepvec (TVEC) (DRUG).
Who is sponsoring clinical trial NCT03597009?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.